MINDMED ANNOUNCES APPOINTMENT OF ANDREAS KREBS AND CAROL VALLONE AS DIRECTORS AND TRANSITION OF BRUCE LINTON
The Mind Medicine Inc. board of directors has appointed Andreas Krebs and Carol Vallone as directors of the company, effective immediately.
Mr. Krebs is an internationally experienced executive, entrepreneur and best-selling author ("The Illusion of Invincibility"). He heads the family-owned investment company Longfield Invest (Langenfeld/Germany), which focuses on growth companies in various industries as well as in the new economy. He has worked in seven countries, in Latin America, Asia and Canada and as president and executive board member of Wyeth Corp. in the United States. Mr. Krebs was chairman of the supervisory board and shareholder council of Merz Pharma, Frankfurt am Main, Germany, from 2010 to 2019, is currently a member of the supervisory board of the European eye clinic group Veonet (Nordic Capital Group) and holds other board positions across various sectors. Furthermore, he serves as chairman of the private non-governmental organization, Forderverein Girassol eV, which supports children and young people from socially difficult backgrounds in Sao Paulo, Brazil.
Ms. Vallone is a well-known business leader, former chief executive officer and corporate board director, with a strong record in launching, scaling and selling global companies. Currently, she serves as chair of the board of trustees at McLean Hospital, the No. 1 ranked freestanding psychiatric hospital and largest psychiatric affiliate of Harvard Medical School; serves on the board of trustees at MGH Institute of Health Professions; and serves on the finance committee at Mass General Brigham. Additionally, Ms. Vallone serves as a board member for the publicly traded Cresco Labs, and for a Bain Capital Double Impact portfolio company, Arosa. She is also an advisory director for the investment firm Berkshire Partners and an advisory board member of the health care-focused venture growth firm Longitude Capital. A serial entrepreneur, Ms. Vallone has served as founder and CEO of global e-learning companies, held manager positions in leading corporate technology companies and served on the boards of public financial services and e-commerce organizations.
Mr. Krebs said: "Mental health issues directly or indirectly impact almost every one of us at some point in our lives. I'm thrilled at the opportunity to help MindMed find better solutions to this huge challenge in the coming years."
Ms. Vallone said, "I feel privileged to support MindMed's esteemed team of scientists and business professionals in the pursuit of new medicines and therapies for those who suffer with mental illness."
Effective Sept. 29, 2021, Bruce Linton stepped down from the company's board of directors in order to make room for the appointment of Ms. Vallone and Mr. Krebs. Mr. Linton said, "In a little over two years MindMed has gone from a topic that was frankly difficult to find support for, to attracting world-class talent and deep capacity capital." He added further, "I am delighted with the candidates joining and look forward to the world of change MindMed can achieve."
MindMed chair Perry Dellelce said: "We are extremely happy to welcome Carol and Andreas to the board. The depth of their collective experience with pharma, tech and health-focused organizations, combined with their extensive service on public company boards, will broaden and deepen the capabilities of the company's board of directors. As well, on behalf of the board of directors I would like to thank Bruce for his committed support and service on the company's board since the company's inception. I look forward to working with him on his next ventures."
The appointments of Mr. Krebs and Ms. Vallone are subject to regulatory approval.